Articles From: FCB Financial Holdings, Inc. Sets Earnings Release and Conference Call Date for Fourth Quarter 2014 Results to FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary Angioedema


2015/1/15
FCB Financial Holdings, Inc. (NYSE:FCB) today announced that it will release its fourth quarter 2014 financial results on Thursday, January 29, 2015 after close of market, and management will host a conference call at 5:00 p.m. Eastern Time that same day.
Sign-up for FCB Financial Holdings, Inc. Sets Earnings Release and Conference Call Date for Fourth Quarter 2014 Results investment picks
2015/2/25
FCB Financial Holdings, Inc. (NYSE:FCB) (the "Company") today announced that Kent Ellert, CEO and President, will host meetings at the Deutsche Bank Mid-Cap Banks Summit in New York City on Thursday, March 12, 2015.
Sign-up for FCB Financial Holdings, Inc. to Present at Deutsche Bank Mid-Cap Banks Summit investment picks
2015/1/30
By Thomas Gryta AT&T Inc. spent $18.2 billion in the latest sale of U.S. wireless licenses, easily topping other bidders and capping a yearlong spending spree that has raised concerns the telecom giant is getting stretched.
Sign-up for FCC names winning bidders in wireless spectrum auction investment picks
2014/12/19
By Gautham Nagesh Chairman Tom Wheeler hopes changes allow consumers to buy channels a la carte The Federal Communications Commission Friday proposed new regulations on companies that provide subscription video services over the Internet, a move to give the companies access to more TV programming and allow them to compete with cable and satellite.
Sign-up for FCC proposes rules for online video services providers investment picks
2015/1/29
By Thomas Gryta Winning bidders in record spectrum auction won't be known for days The Federal Communications Commission's biggest ever auction of wireless spectrum closed Thursday and raised a record $44.9 billion, a boon for taxpayers and a sign of the growing cost of supporting Americans' smartphone habit.
Sign-up for FCC raises record $44.9 billion in U.S. wireless spectrum sale investment picks
2015/2/26
The Federal Communications Commission on Thursday voted in favor of so-called net neutrality rules.
Sign-up for FCC votes in favor of net-neutrality regulations investment picks
2015/2/26
WASHINGTON , Feb.
Sign-up for FCC Votes to Preserve and Protect the Open Internet with Title II Regulation investment picks
2015/2/20
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental New Drug Application (sNDA)for RAPAMUNE® (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive lung disease in women of childbearing age that is often fatal.
Sign-up for FDA Accepts Supplemental New Drug Application for Priority Review of RAPAMUNE® (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM) investment picks
2014/12/9
PHOENIX and VANCOUVER, British Columbia, Dec.
Sign-up for FDA Approves a Safer Way to Administer Vaccines investment picks
2014/12/19
By Peter Loftus AbbVie's Viekira Pak, a cocktail of several drugs, cured more than 90% of most common form of hepatitis C U.S. regulators on Friday approved AbbVie Inc.'s new multidrug regimen for hepatitis C, the latest in a wave of new medicines that is transforming treatment of the liver disease.
Sign-up for FDA approves AbbVie's hepatitis treatment investment picks
2015/2/27
Allergan, Inc. (NYSE: AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market NATRELLE INSPIRA™ round gel-filled smooth breast implants.
Sign-up for FDA Approves Allergan’s NATRELLE INSPIRA™ Round Gel-Filled Breast Implants investment picks
2014/12/8
This Approval Provides a New Treatment Option for a Patient Population With High Unmet Medical Need THOUSAND OAKS, Calif.
Sign-up for FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy investment picks
2014/12/3
BLINCYTO is the First-and-Only Bispecific CD19-Directed CD3 T-Cell Engager (BiTE®) Immunotherapy to be Approved by the FDA BLINCYTO (Blinatumomab) for Injection Will be Available as a 35 mcg Single use Vial THOUSAND OAKS, Calif.
Sign-up for FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia investment picks
2014/12/22
By Ron Winslow U.S. regulators Monday approved Bristol-Myers Squibb Co.'s Opdivo for advanced skin cancer, the latest drug to reach the market in the emerging field of cancer immunotherapy.
Sign-up for FDA approves Bristol-Myers's skin cancer treatment Opdivo investment picks
2015/1/12
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that the Center for Biologics Evaluation and Research (CBER), a division of the U.S. Food and Drug Administration (FDA), has given final approval to its application for an Investigational Device Exemption (IDE) to begin a pivotal trial (the “STAR trial”) to evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma.
Sign-up for FDA Approves Cytori U.S. Pivotal Scleroderma Trial investment picks
2015/1/26
DexCom, Inc., (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its Dexcom G4 ® PLATINUM Continuous Glucose Monitoring System with Share.
Sign-up for FDA Approves Dexcom G4 Platinum Continuous Glucose Monitoring System with Share investment picks
2014/12/12
By Angela Chen The U.S. Food and Drug Administration has approved Eli Lilly Co.'s Cyramza to treat non-small cell lung cancer, the most common type of lung cancer.
Sign-up for FDA approves Eli Lilly's Cyramza for lung cancer investment picks
2015/2/26
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that it received approval from FDA to expand the number of Scleroderma clinical trial sites from 12 to 20 centers in the United States.
Sign-up for FDA Approves Expansion of Pivotal Scleroderma STAR Trial to 20 Clinical Sites investment picks
2014/12/16
Cerus Corporation (NASDAQ: CERS) today announced that the U.S. Food and Drug Administration (FDA) has approved the INTERCEPT Blood System for plasma.
Sign-up for FDA Approves INTERCEPT Blood System for Plasma investment picks
2014/12/4
Incyte Corporation (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi ® (ruxolitinib) for the treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.
Sign-up for FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera investment picks
2014/12/23
Teva Pharmaceutical Industries Ltd.
Sign-up for FDA Approves Teva’s GRANIX® (tbo-filgrastim) Injection for Self-Administration investment picks
2014/12/15
SALT LAKE CITY, Dec.
Sign-up for FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan for LPCN 1021 investment picks
2015/2/18
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for REVLIMID ® (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma (NDMM). REVLIMID plus dexamethasone was previously approved in June 2006 for use in multiple myeloma patients who have received at least one prior therapy.
Sign-up for FDA Expands Indication for REVLIMID® (Lenalidomide) in Combination with Dexamethasone to Include Patients Newly Diagnosed with Multiple Myeloma investment picks
2015/2/2
bluebird bio, Inc. (Nasdaq:BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LentiGlobin ® BB305 Drug Product for the treatment of transfusion-dependent patients with beta-thalassemia major.
Sign-up for FDA Grants Breakthrough Therapy Designation to LentiGlobin for Treatment of Beta-Thalassemia Major investment picks
2014/12/10
Cytori Therapeutics, Inc. (NASDAQ:CYTX) today announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval for an Investigational Device Exemption (IDE) for a pivotal clinical trial, named the ‘STAR’ trial, to evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 patients in the United States.
Sign-up for FDA Grants Cytori Conditional Approval for a U.S. Pivotal Clinical Trial in Scleroderma investment picks
2015/1/26
RESEARCH TRIANGLE PARK, N.C., Jan.
Sign-up for FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary Angioedema investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: FCB Financial Holdings, Inc. Sets Earnings Release and Conference Call Date for Fourth Quarter 2014 Results to FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary Angioedema
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent